Kornimate/medical-research-clean huggingface dataset:
nomad p-kafo study

Conditions: Cerebrovascular Accident; Post-polio Syndrome; Spinal Cord Injuries; Multiple Sclerosis; Muscular Dystrophy; Paralysis

Summary: the goal of this clinical trial is to evaluate the impact of using the nomad powered kafo in people who have had a musculoskeletal or neurological injury that has affected their ability to walk. the main questions it aims to answer are to quantify the effectiveness of the nomad in improving mobility, balance, frequency of falls, and quality of life in individuals with lower-extremity impairments compared to their own brace, over three months of daily home and community use. participants will: * wear a sensor that records everyday activities and mobility. * perform measures of mobility and different activities of participation using their own brace. * perform measures of mobility and different activities of participation using the nomad powered kafo


Eligibility criteria:
inclusion criteria: * regular and compliant use of a unilateral or bilateral kafo or sco or other passive kafos for impairment due to neurological or neuromuscular disease, orthopedic disease, or trauma * cognitive ability to understand and follow the study protocol; willingness to provide informed consent * willing to wear and charge an activity monitor for three-months home trials. exclusion criteria: * flexion contracture in the knee and/or hip joint in excess of 15 degrees * non-correctable knee varus/valgus in excess of 15 degrees * severe spasticity * inability to stabilize the trunk with or without assistive devices (crutches, canes, etc.)
the effects of vacuum-compression therapy on the healing of diabetic foot ulcers

Conditions: Diabetic Foot Ulcer

Summary: the objective of this study is to evaluate the impact of vacuum-compression effects of vasotrain on the diabetic foot ulcers using stereological method based on cavalieri's principle in diabetic patients.

diabetic foot ulcers are common and serious complications of chronic diabetes mellitus. the prevalence of foot ulcers among patients with diabetes is 15%. the length of hospital stay is approximately 60% longer among patients with foot ulcers, as compared with those without ulcers. diabetic foot ulcers accounts for \>50% of all nontraumatic lower-leg amputations.although, current preventive methods and treatment modalities have been effective in healing foot ulcers, statistics show high incidence of foot ulcers and amputations in individuals with diabetes.on the other hand, only a few studies were performed on the effects of vasotrain in healing diabetic foot ulcers. the use of the machine enhances the delivery of oxygen and nutrients to the area, which in turn, facilitate wound healing

Eligibility criteria:
inclusion criteria: * a diabetic foot ulcer corresponding to grade 2 * no history of deep venous thrombosis and no hemorrhage in ulcer exclusion criteria: * significant loss of protective sensation * hemorrhage during treatment * vertigo * no completion of treatment

Keywords: diabetic foot ulcer vacuum compression therapy stereology ulcer area vasotrain random controlled trial.
effect of multidimensional physiotherapy in chronic nonspecific low back pain

Conditions: Low Back Pain, Mechanical

Summary: this study compares the effect of multidimensional physiotherapy to usual evidence-based physiotherapy in the treatment of chronic nonspecific low back pain in adults. half of the participants will receive multidimensional physiotherapy based on biopsychosocial approach while the other half will receive usual evidence based physiotherapy.

multidimensional physiotherapy treatment include: psychoeducation based on cognitive behavioral therapy (cbt), education, graded exposure, postural correction exercise, lifestyle change, and electrotherapy. usual evidence-based physiotherapy include: electrotherapy, education, and trunk general exercises.

Eligibility criteria:
inclusion criteria: * age between 18-50 * low back pain for 3 months or more * disability based on oswestry disability index (odi) between 20-60 * fear of movement based on tampa scale of kinesiophobia \>37 * minimum level of education * native persian speaking exclusion criteria: * any evidence of e specific medical diagnosis * rheumatoid disease,fibromyalgia, neuropathy, progressive neurological disease * history of headache, dizziness, nausea, epilepsy, migraines and mental disorder * beck's anxiety inventory\> 26 * beck's depression inventory ii\> 29 * pregnancy * having other therapies during the present research

Keywords: pain disability pain catastrophising quality of life fear of movement chronic non specific low back pain
the potential role of ga-68-psma in staging, restaging and monitoring response in primary liver cancer: comparison with f-18-fdg

Conditions: Hepatocellular Carcinoma (HCC)

Summary: hepatocellular carcinoma (hcc) is the fifth most common cancer and the second leading cause of cancer-related deaths in the world. hepatitis c virus (hcv) is the most common underlying cause of cirrhosis and hcc in the western world. the staging of the disease is done by combining blood tests and imaging tests. ultrasound scanning, computed tomograph (ct) and magnetic resonance imaging (mri) scans are methods based on identifying or significant change in the liver. those changes are sometimes difficult to identify, especially when there are changes in liver structure resulting from disease, such as cirrhosis of the liver. in many cases it is also difficult to detect secondary scattering in anatomical tests, such as identifying a disease in normal size lymph nodes or early skeletal dissociation. functional imaging is not based on structural changes, but on the ability to detect changes in the function and properties of the tissue, such as a change in the cell's metabolic consumption or the presence of proteins that characterize the tumor tissue.pet scans can show tumor cell activity (the cancer cells are more aggressive, get more sugar and therefore see more absorption in pet), detect small tumors and metastases outside the liver (because they do a whole body test). to complete this test, a ct scan is also performed on the same device (pet-ct scanner). there is a new material called prostate-specific mrna that is marked with gallium isotope (ga-68-psma). it is the substance that is absorbed into the cells of the blood vessels of the tumor. the ga-68-psma is now widely used in the diagnosis of prostate cancer. the new researches also found the possibility of using ga-68-psma in primary liver cancer in patients because of the over-expression of the antigen in the blood vessels. therefore, the tests with ga-68-psma and f-18-fdg will complement each other and will give a complete picture of the extent of the disease. each patient has individual characteristics of the tumor, and according to the results it will be possible to adapt the test to the patient with the appropriate material for the disease and this will be effective for the decision to treat and follow up. at the end of the study it will be possible to offer the study participant the appropriate functional imaging test.


Eligibility criteria:
inclusion criteria: * 16 patients diagnosed with hcc. exclusion criteria: * minors under the age of 18 * pregnant women * people without primary liver cancer
psychological influences on postoperative recovery

Conditions: Care, Postoperative; Pain, Postoperative; Surgical Procedures, Operative; Otorhinolaryngologic Surgical Procedures; Tonsillectomy; Adenoidectomy

Summary: the primary hypothesis tested in this project is that the preoperative behavioral stress response predicts postoperative behavioral and clinical recovery of children undergoing surgery.


Eligibility criteria:
inclusion criteria: * outpatient tonsillectomy or tonsils/adenoids * asa i, ii exclusion criteria: * developmental delay * asa iii-iv * psychotropic medication * meds which interfere with metabolism of midazolam * 36 weeks gestation
patient-ventilator asychrony during non-invasive ventilation when copd patients doing exercise

Conditions: COP; Non-invasive Ventilation; Pulmonary Rehabilitation

Summary: pulmonary rehabilitation programmes including aerobic exercise training have strong evidence of effectiveness in improving exercise capacity, dyspnoea and hrql in patients with copd. therefore, current guidelines recommend pulmonary rehabilitation, including exercise training, in these patients. non-invasive ventilation(niv) is increasingly used during exercise training programmes in order to train patients at intensity levels higher than allowed by their clinical and pathophysiological conditions. patient-ventilator asynchrony (pva) describes the poor interaction between the patient and the ventilator and is the consequence of the respiratory muscle activity of the patient being opposed to the action of the ventilator.pva have unfavourable clinical impace on gas exchange, dyspnoea perception, patient comfort and tolerance and reduced adherence to niv. this study is going to detect whether the pva will increase when copd patients exercise with niv supporingt


Eligibility criteria:
inclusion criteria: 1. age 40-80, males and females; 2. stage iii and iv copd; 3. similar with non-invasive ventilation; 4. willing to participate in the study; 5. able to provide informed consent. exclusion criteria: 1. presented with an acute exacerbation during previous 3 months; 2. bronchiectasis; post-tuberculosis sequelae; rib cage deformities; neuromuscular disorders; and bronchial carcinoma. 3. intolerant with niv

Keywords: patient-ventilator asynchrony
to evaluate efficacy and safety of hlx10 in combination with chemotherapy versus placebo in combination with chemotherapy as neoadjuvant therapy and hlx10 versus placebo as adjuvant therapy in patients with triple negative breast cancer (tnbc)

Conditions: Triple Negative Breast Cancer

Summary: this study is a randomized, double-blind,international multi-centre, phase iii clinical study to evaluate efficacy and safety of hlx10 in combination with chemotherapy versus placebo in combination with chemotherapy as neoadjuvant therapy and hlx10 versus placebo as adjuvant therapy in previously untreated and potentially resectable patients with tnbc and without distant metastasis. eligible subjects in this study will be randomized to arm a or arm b at 2:1 ratio as follows: arm a (hlx10 arm): hlx10 + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → hlx10 + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → hlx10 (9 cycles) arm b (placebo arm): placebo + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → placebo + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → placebo (9 cycles) the three stratification factors for randomization include: lymph node metastasis (yes or no), size of primary tumor lesion (t1/t2 or t3/t4), asian population (yes or no).


Eligibility criteria:
inclusion criteria: 1. subjects histologically diagnosed with previously untreated tnbc (lack of human epidermal growth factor receptor-2 \[her2\], estrogen receptor \[er\], progesterone receptor expression as determined by the study site). 2. subjects who are judged as one of the following by the american joint committee on cancer (ajcc) within 4 weeks prior to randomisation: 1. t1c, n1-n2, m0 2. t2, n0-n2, m0 3. t3, n0-n2, m0 4. t4a-c, n0-n2, m0. 3. major organs are functioning well 4. participant must keep contraception exclusion criteria: 1. subjects with any other active malignancy within 5 years prior to signing the informed consent form or at the same time. localised tumours that have been cured such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder carcinoma, and cervical cancer in situ are acceptable. 2. subjects who have received chemotherapy, targeted therapy, or radiotherapy within 12 months prior to the initial dose of the investigational product. 3. subjects with a history of severe allergy to any monoclonal antibody or investigational product and its excipient. 4. pregnant or lactating women. 5. subjects with a known history of psychotropics abuse or drug abuse 6. subjects presenting other factors not suitable for participation as judged by the investigator.

Keywords: triple negative breast cancer previously untreated potentially resectable without distant metastasis
randomized study to evaluate the effect of an investigational product on weight loss and body composition

Conditions: Obesity

Summary: this is a pilot study to determine the safety and efficacy of an investigational product (ihbg-10) on weight loss, and changes in body composition.

subjects will be randomized to one of two groups: one group will take 500 mg of the investigational product (ihbg-10) 15 minutes prior to the three main meals of the day; the other group will take placebo 15 minutes prior to the three main meals of the day. subjects will be on the investigational product or placebo for 12 weeks. participation in this study involves four study visits.

Eligibility criteria:
inclusion criteria: * age 18 and older * body mass index of 30 or greater * agree to keep diet, exercise and all current health habits stable during participation in the study exclusion criteria: * women who are pregnant, breastfeeding or planning to become pregnant * prior bariatric surgery * use of prescription or over-the-counter appetite suppressants, herbal products or other medications for weight loss within the past month * obesity as a result of a clinically diagnosed endocrine problem * currently taking an anti-psychotic medication * history of peptic ulcer disease

Keywords: obesity weight loss weight management overweight nutriceutical
development of clinical assessment technique using multi-radiotracer pet/mr in prostate cancer

Conditions: Prostate Cancer Recurrent; Stage II Prostate Carcinoma; Stage III Prostate Carcinoma

Summary: to development of clinical assessment technique using multi-radiotracer positron emission tomography/magnetic resonance (pet/mr) in prostate cancer * to establish the optimal imaging technique of pet/mr using multiple radioactive tracers for prostate cancer * to establish the imaging biomarker using pet/mr for clinical assessment of prostate cancer and early detection of recurrent prostate cancer

to establish the optimal imaging technique of pet/mr using multiple radioactive tracers for prostate cancer * recruiting 30 patients with prostate cancer ahead to radical prostatectomy * pet/mr using 18f-choline with dedicated prostate mri in all patients * pet/mr using 18fluoride(f)-fluorodeoxyglucose(fdg)in all patients after 2-7 days * pet/ct using 18f-fdg in all patient immediate after 18f-fdg pet/mr * outcome assessment: comparison of scan time, image quality, tumor detection rate, standardized uptake values of lesions * establishing optimal imaging technique for prostate pet/mr to establish the imaging biomarker using pet/mr for clinical assessment of prostate cancer * comparison of findings on pet/mr, mri and pet/ct with pathological mapping after radical prostatectomy * outcome assessment: accuracy of pet/mr for localization and staging of prostate cancer compared with mri only and pet/ct only to establish the imaging biomarker using pet/mr for early detection of recurrent prostate cancer * recruiting 15 patients with recurrent prostate cancer treated by surgery, hormone, or radiation therapy * recruiting 15 patients with treated prostate cancer without recurrence * pet/mr using 18f-choline with dedicated prostate mri in all patients * pet/mr using 18f-fdg in all patients after 2-7 days * pet/ct using 18f-fdg in all patient immediate after 18f-fdg pet/mr * comparison of findings on pet/mr, mri, and pet/ct with clinical data in two patient groups with or without recurrent prostate cancer * outcome assessment: accuracy of pet/mr for early detection and localization of recurrent prostate cancer compared with mri only and pet/ct only

Eligibility criteria:
inclusion criteria: * patient with prostate cancer before treatment * patient with prostate cancer treated * patient with prostate cancer recurrent exclusion criteria: * patient with contraindication for mri * patient with severe renal impairment

Keywords: prostate cancer mri pet
use of the "game-ready" splint for better recovery in primary total shoulder arthroplasty

Conditions: Shoulder Osteoarthritis

Summary: the aim of the study is to compare the level of postoperative pain after fitting the game ready splint, at 48 hours versus that observed with fitting a standard splint


Eligibility criteria:
inclusion criteria: 1. first-line reverse prosthesis 2. without prosthetic history 3. patient who has given his consent to participate in the observational study after being informed by the surgeon 4. patient living in france and able to answer the questionnaire alone. 5. subject affiliated to a social security scheme or beneficiary of such a scheme 6. lack of participation in another clinical study exclusion criteria: 1. minor patient 2. major subject protected by law, under curatorship or tutorship 3. anterior prosthesis 4. infection 5. parkinson's, degenerative neurological disease 6. pregnant or breastfeeding woman
mortality following surgery for proximal femoral fractures

Conditions: Fracture of Neck of Femur (Hip)

Summary: proximal femoral fractures are most frequent traumatologic and orthopedic diagnoses undergoing surgery. it affect most seniors and accompanied by a series of complications. the aim of our retrospective clinical trial is to establish a thirty-day mortality rate after surgical solutions, mortality during hospitalization and compare the types of anesthesia chosen during the performance (general vs. subarachnoid anesthesia).

we evaluate relationship between the monitored parameters and 30 day survival. observed parameters: * age of the patient * sex of the patient * 90 days mortality rate * american society of anesthesiologists (asa) score * time since injury and surgery (hours) * whether surgery was initiated during the day (7:00 - 20:00) or at night (20:00-07:00) * type of administered anesthesia (ga, epidural anaesthesia, subarachnoid (spinal) block) * hemoglobin level prior to surgery * haemotransfusion administration during surgery * perioperative administration of vasopressors * anesthetist erudition (with / without accomplished residency) * surgeon erudition (with / without accomplished residency)

Eligibility criteria:
inclusion criteria: * isolated fracture of proximal femur indicated for surgery exclusion criteria: * children under 18 years * none isolated trauma * isolated fracture of proximal femur without surgery

Keywords: hip fracture proximal femur pertrochanteric fracture subtrochanteric fracture subcapital fracture safety issue anesthesia
healthy immigrant community: mobilizing the power of social networks

Conditions: Weight Loss

Summary: the objective of this study is to leverage existing social networks for health behavior change relevant to obesity and cardiovascular risk among immigrant populations in southeast, minnesota.


Eligibility criteria:
inclusion criteria: * self-identification as hispanic or somali. * member of a social network identified in the social network analysis. * willingness to participate in all aspects of the study. * provision of informed consent. exclusion criteria: * pregnancy at the time of enrollment. * serious medical conditions or disabilities that would make physical activity difficult. * to avoid stigmatization, a normal weight (bmi\<25) will not exclude individuals from participating in the intervention, but they will be excluded from the measurements and analyses.
voriconazole for ipa in chinese patients with copd

Conditions: Invasive Pulmonary Aspergillosis; COPD

Summary: voriconazole is recommended as first-line therapy for invasive pulmonary aspergillosis, however the efficacy and safety of voriconazole for treating invasive pulmonary aspergillosis secondary to copd is not clear. this study aims to investigate the effectiveness and tolerability of intravenous voriconazole for treatment of invasive pulmonary aspergillosis in chinese patients with copd, by monitoring changes in clinical symptoms, eradication of aspergillus, improvement of chest imaging as well as record of possible adverse reactions following 2-week intravenous instillation of voriconazole.

this is a multiple-center open-label clinical trial to study the efficacy and safety of voriconazole for treating invasive pulmonary aspergillosis secondary to copd in chinese patients.the primary endpoint is treatment success rate as defined by improvement of symptoms related to invasive pulmonary asperillosis, secondary endpoints include the mortality, the eradication of sputum asperillus and profile of adverse reactions following intravenous instillation of voriconazole.

Eligibility criteria:
inclusion criteria: * cases of invasive pulmonary aspergillosis secondary to copd exclusion criteria: * use of voriconazole or itraconazole or amphotericin b or caspofungin or micafungin within 4 weeks prior to enrollment * known allergy to voriconazole * severe impairment of live or kidney function * septic shock * unwilling to sign informed consent

Keywords: voriconazole copd invasive pulmonary aspergillosis efficacy safety
a study of mycophenolate mofetil combined with glucocorticoid therapy in relapse vogt-koyanagi-harada disease

Conditions: Vogt-Koyanagi-Harada Disease; Mycophenolate Mofetil

Summary: this project is designed to test the hypothesis that mycophenolate mofetil is clinically useful for patients with relapse vogt-koyanagi-harada disease

approval of the study was obtained from the hospital's ethical committee. the study design and methodology followed the tenets of declaration of helsinki. all patients were provided with written informed consent and received a thorough explanation of the use of mycophenolate mofetil, its potential risks and benefits. this is a monocenter, cohort, observational study evaluating patients with relapse vkh divided into two groups: mycophenolate mofetil therapy group and traditional therapy group. for mycophenolate mofetil therapy group, an initial dose of 0.5-1.0g bid mmf was orally administered every day, glucocorticoid was started at a dose of 0.5-0.8 mg/kg/day and no more than 60 mg/day. for the traditional therapy group, patients were treated with glucocorticoids alone or glucocorticoids combined with cyclosporine. study participants will be followed for up to one year to determine efficacy and side effects. according to best corrected visual acuity (bcva), anterior chamber and vitreous inflammation, optical coherence tomography (oct), change in corticosteroid dose during the study period and so on. the investigators evaluate the anti-inflammatory and immunosuppressive effects of mmf in treatment of relapse vkh.

Eligibility criteria:
inclusion criteria: 1. subject is 18 to 70 years of age. 2. subjects who do not have previous, active or latent tuberculosis (tb). 3. subject must start vogt-koyanagi-harada disease more than two months, and develop at least one recurrence. exclusion criteria: 1. subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to tb, cytomegalovirus (cmv), human t-lymphotropic virus type 1 (htlv-1), whipple's disease, herpes zoster virus (hzv), lyme disease, toxoplasmosis and herpes simplex virus (hsv). 2. subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial. 3. subject has previous exposure to anti-tumor necrosis factor (tnf) therapy or any biologic therapy (except intravitreal anti-vascular endothelial growth factor \[vegf\] therapy) with a potential therapeutic impact on non-infectious uveitis. 4. subject has received ozurdex® (dexamethasone implant) within 6 months prior to the baseline visit. 5. subject has received intravitreal anti-vegf therapy within 45 days of the baseline visit for lucentis® (ranibizumab) or avastin® (bevacizumab) or within 60 days of the baseline visit for anti-vegf trap (aflibercept). 6. subject has received intravitreal methotrexate within 90 days prior to the baseline visit